Fasting PP was significantly increased in individuals using a sulfonylurea (26.0 (18.3–33.7) pmol/L, p < 0.001) or DPP4 inhibitor (12.2 (4.3–20.0) pmol/L, p < 0.01) at enrolment, adjusted for age, sex, use of other hypoglycaemic agents and diabetes status, consistent with their known effects on PP secretion19 and degradation20; however neither drug class was significantly associated with study endpoints, nor significantly interacted with the relationship between PP and study endpoints, and consequently both were excluded from further statistical analysis. The gene discussed is DPP4; the disease is diabetes mellitus.